Pureos Bioventures is a Swiss-based venture capital firm that invests exclusively in private innovative drug development companies, with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell, and gene therapies.
51% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Average disclosed round size is $94.3M (across 12 rounds with reported amounts).
Portfolio
24
Fund Size
$205M
Top Stage
Series A
Last 12 Mo
2
Team
DL
Dr. Lars Nieba
Venture Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
37 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 AnaCardio | Series B | — | Sep 2026 |
 Adcytherix | Series A | — | Oct 2025 |
 Callio Therapeutics | Series A | $187M | Mar 2025 |
| AnaCardio | Series A | $19M | Jan 2025 |
 Citryll | Series B | — | Dec 2024 |
| AAlentis | Series D | $181.4M | Nov 2024 |
| Adcytherix | Seed | — | Jun 2024 |
| MMemo Therapeutics AG | Series C | — | May 2024 |
 Alentis Therapeutics | Series D | $181.4M | Jan 2024 |
| MMemo Therapeutics AG | Series C | — | Nov 2023 |
| AAriceum Therapeutics | Unknown | — | Apr 2023 |
 Ariceum | Unknown | — | Apr 2023 |
 Minervax | Series B | — | Dec 2022 |
 Tridek One | Series A | — | Sep 2022 |
| TTridek-One | Unknown | — | Sep 2022 |
| IImCheck Therapeutics | Series C | — | Jun 2022 |
| Ariceum | Series A | — | Jun 2022 |
| AAriceum Therapeutics | Series A | — | Jun 2022 |
 Engimmune Therapeutics | Seed | — | May 2022 |
| AAriceum Therapeutics | Series A | — | Jan 2022 |
 Araris Biotech | Unknown | $24M | Jan 2022 |
| Engimmune Therapeutics | Seed | — | Jan 2022 |
 Hummingbird Bioscience | Series C | $125M | May 2021 |
 Corlieve Therapeutics | Seed | — | Nov 2020 |
| Araris Biotech | Seed | — | Oct 2020 |
Page 1 of 2
Top Co-Investors
Bpifrance9 shared
Novo Capital9 shared
Andera Partners7 shared
EQT Life Sciences7 shared
Novo Holdings A/S7 shared
Kurma Partners6 shared
Frazier Healthcare Partners6 shared
Schroders Capital6 shared
Earlybird Venture Capital5 shared
Idinvest Partners5 shared
Redalpine5 shared
RA Capital Management4 shared
HealthCap4 shared
Polaris Partners4 shared
Industrifonden4 shared
OrbiMed4 shared
SEEDS Capital4 shared
EDBI4 shared
Jeito Capital4 shared
Frazier Life Sciences4 shared
Last updated: 20 October 2026